2026-04-14T03:06:56Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2228402025-11-19T22:35:09Zcom_2072_1057col_2072_478916col_2072_478917

http://hdl.handle.net/2445/222840/ore.xml 2025-11-19T22:35:09Z 2025-11-19T22:35:09Z RECERCAT Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study Gratzke, Christian Özgüroğlu, Mustafa Peer, Avivit Sendur, Mehmet A. N. Retz, Margitta Goh, Jeffrey C. Loidl, Wolfgang Jayram, Gautam Byun, Seok-Soo Kwak, Cheol Kwiatkowski, Marek Manneh Kopp, Ray Vázquez Limón, Juan Carlos Escobar Penagos, José Francisco Giorgi, Ugo de Da Trindade, Karine Martins Niu, C. Liu, Y. Poehlein, Christian H. Piulats, Josep M. 2025-11-19T22:35:09Z